Bought this stock a little after the RCT entry after it was spiking quickly past it, based on its news regarding a fully funded clinical study for glaucoma. This stock was spiking nicely after I entered so I sold 1/3 into strength, however, it quickly started dipping, so I had to cut it for a small loss. Good lesson and discipline with cutting losses quickly. It was frustrating but I got out with minimal slippage.